Overhaul Of NDAC Process Needed For Better Switch Chances – Brass
This article was originally published in The Tan Sheet
Executive Summary
FDA should "anchor" advisory committees' evaluations of switch applications by identifying adequate outcomes of behavioral science studies that sponsors submit, according to pharmacology expert Eric Brass